Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 320

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Open access
Herbst, Roy S., Garon, Edward B., Kim, Dong-Wan, Cho, Byoung Chul, Gervais, Radj, Perez-Gracia, Jose L., Han, Ji-Youn, Majem, Margarita, Forster, Martin D., Monnet, Isabelle, Novello, Silvia, Gubens, Matthew A., Boyer, Michael, Su, Wu-Chou, Samkari, Ayman, Jensen, Erin H., Kobie, Julie, Piperdi, Bilal, Baas, Paul · 2021 · Journal of Thoracic Oncology

Abstract

INTRODUCTION: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy and safety follow-up for the KEYNOTE-010 study. METHODS: once every 3 weeks for up to 35 cycles (2 y). Patients who completed pembrolizumab treatment and subsequently had recurrence could receive second-course pembrolizumab for up to 17 cycles (1 y). Pembrolizumab doses were pooled in this analysis. RESULTS: A total of 1034 patients were randomized (pembrolizumab, n = 691; docetaxel, n = 343). Median study follow-up was 67.4 months (range: 60.0‒77.9). The hazard ratio (95% confidence interval) for OS was 0.55 (0.44‒0.69) for patients with PD-L1 TPS ≥50% and 0.70 (0.61‒0.80) with PD-L1 TPS ≥1%. The 5-year OS rates for pembrolizumab versus docetaxel were 25.0% versus 8.2% in patients with PD-L1 TPS ≥50% and 15.6% versus 6.5% with PD-L1 TPS ≥1%. Among 79 patients who completed 35 cycles/2 years of pembrolizumab, the OS rate 3 years after completion (∼5 y from randomization) was 83.0%. A total of 21 patients received second-course pembrolizumab; 11 (52.4%) had an objective response after starting the second course and 15 (71.4%) were alive at data cutoff. Exploratory biomarker analysis revealed that higher tissue tumor mutational burden (≥175 mutations per exome) was associated with improved outcomes with pembrolizumab. CONCLUSIONS: Pembrolizumab continued to provide long-term benefit than docetaxel in patients with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1%. Our findings confirm pembrolizumab as a standard-of-care treatment in the second-line or later setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.05.001

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 320

Metadata

Authors
Herbst, R. S., Garon, E. B., Kim, D.-W., Cho, B. C., Gervais, R., Perez-Gracia, J. L., Han, J.-Y., Majem, M., Forster, M. D., Monnet, I., Novello, S., Gubens, M. A., Boyer, M., Su, W.-C., Samkari, A., Jensen, E. H., Kobie, J., Piperdi, B., & Baas, P.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-10
Volume
16
Issue
10
Pages
1718-1732
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3165293110
Cited by
320
References
24
FWCI
17.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC. https://app.cochat.ai/papers/10.1016/j.jtho.2021.05.001
The paper
Herbst, R. S., Garon, E. B., Kim, D.-W., Cho, B. C., Gervais, R., Perez-Gracia, J. L., Han, J.-Y., Majem, M., Forster, M. D., Monnet, I., Novello, S., Gubens, M. A., Boyer, M., Su, W.-C., Samkari, A., Jensen, E. H., Kobie, J., Piperdi, B., & Baas, P. (2021). Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.05.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.